Market Overview

Research and Markets: Japan Pharmaceuticals and Healthcare Report Q4 2012


Research and Markets ( has announced the addition of the "Japan Pharmaceuticals and Healthcare Report Q4 2012" report to their offering.

BMI View:

Considering Japan's lacklustre economic trajectory and recently unsettled political environment, as well as its extremely challenging demographic profile, the country's healthcare market can be considered highly efficient in global terms. We expect cost containment to become a more common theme. We see commercial upside potential for generic drug firms and manufacturers of medical devices that aid non-institutional chronic disease management and improve independence among elderly patients.

About This Report:

The Japan Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Japan's pharmaceuticals and healthcare industry.

Key Topics Covered:

Executive Summary

SWOT Analysis

Pharmaceutical Risk/Reward Ratings

Japan: Market Summary

Industry Forecast Scenario

Competitive Landscape

Pharmaceutical Industry

Company Profiles

Demographic Outlook


BMI Methodology


Companies Mentioned:

- Astellas

- AstraZeneca

- Daiichi Sankyo

- Eisai

- GlaxoSmithKline

- Merck & Co (Banyu)

- Mitsubishi Tanabe

- Multinational Companies

- Novartis

- Pfizer

- Sanofi

- Sawai Pharmaceutical

- Takeda Pharmaceutical Company

For more information, including full list of companies mentioned, please visit

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

View Comments and Join the Discussion!